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ABSTRACT
Objective: The purpose of this prospective 
randomized study was to evaluate the impact of 
adding alendronate to hormone replacement 
therapy (HRT) in established postmenopausal 
osteoporosis.
Patients: Forty patients were randomly assigned 
to receive either 0,625 mg. conjugated estrogen 
with 2,5 mg. medroxyprogesterone acetate 
(HRT) alone or HRT combined with 10 mg. 
alendronate daily for one year. Both groups 
received a daily supplement of 500 mg. of 
elemental calcium. Bone mineral density of 
lumbar spine and femur neck were measured 
prior to treatment and at the end of one year by 
dual energy X-ray absorptiometry.
Results: Nineteen patients from alendronate and 
HRT group, 18 patients from HRT group 
completed the study. HRT group had an increase 
in bone mineral density of 7,5±0,02% at lumbar 
spine (p<0.01) and 11,6±0,04% at femur neck 
(p<0,001). Whereas alendronate and HRT group 
had a mean increase in bone mineral density of 
7,8±0,02% at lumbar spine (p<0.01) and 
17,8±0,02% at femur neck (p<0.01). Both 
treatments were well tolerated.
Conclusions: Both HRT alone and HRT 
combined with alendronate treatments in 
postmenopausal osteoporosis appears to
increase bone mineral density at spine and femur 
neck. There is a greater increase in bone mineral 
density at femur with HRT alendronate 
combination treatment which did not achieve 
significance.
Key W ords: Alendronate, Hormone
replacement therapy, Bone density
INTRODUCTION
Postmenopausal osteoporosis is a common 
disorder characterized by an increase in bone 
resorption relative to bone formation with an 
increased rate of bone turnover (1). It is a 
common and important cause of morbidity and 
mortality among postmenopausal women, 
affecting approximately 28 million individuals in 
the United States (2). The incidence of hip 
fractures increases with age, rising from 0.3/1000 
to 20/1000 from 45 to 85 years (3). White women 
have approximately 16% lifetime risk of having 
hip fracture. Hip fractures alone occur in more 
than 300.000 women per year in the United 
States with a mortality of 40.000 women annually 
and an associated cost of billions of dollars (3).
Postmenopausal hormone therapy has a 
beneficial impact on the risk of cardiovascular 
disease, cognitive function, atrophic changes as 
well as prevention and treatment of osteoporosis
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(4-6). Postmenopausal Estrogen Progestin 
Interventions (PEPI) (6) trial demonstrated that 
hormone replacement therapy had a gain of 5% 
in bone mineral density in spine and 2% in the 
femur neck compared with a 2% loss in placebo 
group at the end of three years.
Bisphosphonates are effective in preventing 
bone loss by inhibiting bone resorption, 
increasing bone density in both the spine and the 
hip in normal postmenopausal women (7-11). In 
women with osteoporosis, alendronate reduced 
the risk of nonvertebral fractures by 30% and 
vertebral fractures 90% in the first 3 years of 
treatment (7). There are numerous studies 
demonstrating the effectiveness of both HRT and 
alendronate in the treatment of osteoporosis 
individually (5-9). However, the literature on the 
impact of combining alendronate to HRT in the 
treatment of postmenopausal osteoporosis is 
very scarce. The purpose of this prospective 
study was to evaluate the impact of adding 
alendronate to hormone replacement therapy in 
established osteoporosis.
METHODS
Forty women at least 3 years postmenopausal 
and with established osteoporosis (defined as a 
bone mineral density of the lumbar spine and 
femur at least 2,5 standard deviation below the 
mean value in premenopausal women) 
presented to the Marmara University Hospital, 
Menopause Clinic were included in this study. 
Informed consent was obtained from all subjects, 
and the study was approved by the Institutional 
Review Board of the Marmara University School 
of Medicine. None of these patients smoked and 
there was no history of prior treatment of 
bisphosphonates, calcitonin or hormone 
replacement therapy. Women with vitamin D 
deficiency, Paget's disease, hyperparathyroidism, 
who were treated with glucocorticoids, who had 
systemic disease and abnormal renal or hepatic 
function were excluded from the study.
Subjects were randomly assigned according to 
1/1 ratio to receive either 0.625 mg conjugated 
estrogen with 2.5 mg medroxyprogesterone 
acetate (Premelle, Wyeth-Ayerst, USA) (HRT) 
alone or HRT combined with 10 mg alendronate 
(Fosamax, Merck Sharp&Dohme, New Jersey,
USA) daily for one year. Both groups received a 
daily supplement of 500 mg of elemental calcium. 
Height and weight of all patients were recorded 
initially. Patients were recalled at first, third and 
sixth month to assess drug compliance.
Bone mineral density of L2 - L4 lumbar spine and 
left femur neck were measured by dual energy X 
ray absorptiometry with use of DPX (Lunar, 
Madison Wl, USA) densitometer prior to 
treatment and at the end of one year. 
Technicians who measured bone density were 
blind to treatment regimes. Coefficients of 
variation for the densitometer were 1% for the 
spine and 2.2% for the proximal femur in vivo. 
Scans were analysed with 1.3 version software.
For statistical analysis, paired t test is used for 
within group comparisons and Mann Whitney test 
is used for between group comparisons. P values 
are two sided.
RESULTS
The baseline characteristics of forty women 
between the ages of 45 and 67 years are shown 
in Table I. The treatment groups did not differ 
significantly in age, years since menopause, 
body mass index, bone mineral density of spine 
and femur. Nineteen patients from HRT and 
alendronate group, 18 patients from HRT group 
completed the study.
There were significant increases in bone mineral 
density of the spine and femur neck at 12 months 
in both HRT and HRT with alendronate group. At 
the end of one year HRT and alendronate group 
had increased their bone density 7.8±0.02 
percent at lumbar spine (p<0.01) and 17.8±0.02 
percent at femur neck (p<0.01). HRT group had 
a mean increase in bone mineral density of 
7.5±0.02 percent at lumbar spine (p<0.01) and 
11.6±0.04 percent at femur neck (p<0.01) (Figs.
I and II). Alendronate and HRT combination 
treatment produced greater increase in bone 
mineral density, especially at femur, than HRT 
alone, but the differences were not statistically 
significant.
Both alendronate and HRT were well tolerated. 
Two patients in HRT and alendronate group 
experienced mild stomach pain. One patient from
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HRT group and two patients from HRT with 
alendronate group complained of breast 
tenderness, which disappeared within a few 
months. Five patients (25%) from HRT and 6 
patients (30%) from HRT with alendronate group 
had breakthrough bleeding. Nevertheless only 2 
of them, one from each group, discontinued 
therapy within 3 months due to breakthrough 
bleeding. One patient from HRT group dropped 
out because of social reasons.
Table I. Baseline Characteristics ot the Study Participants
C hracterist ics H R T  and A l e n d r o n a t e  
M e a n
H R T
M e a n
P
A ge 5 5 ,6 ± 5 ,3 5 4 ,7 ± 5 N S
Years  since m en o pa u s e 9,1 ±1,1 10,1±1,2 NS
BMI 2 4 ,2± 2 .8 2 5±3 N S
Bone mineral density (g / cm 2 )  
L u m b a r  spine 0 ,8 7 5 ± 0 ,0 8 0,875±0,1 N S
F e m u r 0,7 70 ± 0 ,1 0 ,7 6 7 ± 0 ,0 8 N S
* Values are m e a n s  ± S D  
** N S :  N o n  -  Significant
F ig . l .s  The percent of change in bone mineral density in 
femur in both HRT and HRT with alendronate group at 
the end of one year.
Fig .2  The percent of change in bone mineral density in 
spine in both HRT an HRT with alendronate group at 
the end of one year.
DISCUSSION
The present study demonstrated that both HRT 
alone and HRT combined with alendronate 
treatments significantly increased bone mineral 
densities of spine and femur neck in 
postmenopausal established osteoporosis. The 
percent of increase in bone mineral density of the 
spine at one year is similar in both groups (7.8% 
vs 7.5%). There is a trend towards a greater 
increase in bone mineral density of femur at one 
year with alendronate and HRT treatment which 
did not achieve significance, (17.8% vs 11.6%).
Estrogen therapy has been the mainstay for the 
prevention and treatment of postmenopausal 
osteoporosis (1). A large body of data shows that 
estrogen either maintains bone or slows bone 
loss and thereby prevents osteoporotic fractures 
(1 ). In the PEPI trial at the end of three years, the 
women receiving hormone treatment had 
experienced about a 5% gain in bone mineral 
density in the spine and 2% in the hip compared 
with approximately a 2% loss in the placebo 
group (6). In a 10 year follow up study of women 
receiving estrogen-progestin treatment therapy, 
the spinal bone density steadily increased, 
reaching a level of 13% over baseline after 10 
years of treatment (12).
Bisphosphonates are effective in preventing 
bone loss by inhibiting bone resorption. The first 
generation of bisphophonates also inhibited bone 
mineralization and therefore intermittent therapy 
was necessary. The second generation of 
bisphosphonates allows bone formation to occur 
while inhibiting bone resorption. A multicenter 
randomized placebo controlled trial of 
alendronate 5 or 10 mg/day for 2 years, 20 or 40 
mg/day given for 1 year produced a significant 
increase in the BMD of the lumbar spine of 
postmenopausal women (13). In this study, the 
10 mg/day dosage produced a significantly 
greater increase in BMD at the total hip than any 
other dosage. In a 3 years study, Devogelaer et 
al (14) found that over 92% of patients receiving 
alendronate had an increase in spine BMD at 
year 3 compared with baseline. In another study, 
Tucci et al (15) found that 94.3% of patients 
receiving alendronate had an increase lumbar 
spine BMD of >4% and none had a decrease, 
whereas 57.5% of the patients receiving placebo 
showed a loss of spine BMD. Liberman et al (7)
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showed that, there was 8.8% and 5.9% 
difference in bone mineral density at spine and 
femur respectively between alendronate and 
placebo groups at 3 years. The risk of developing 
new vertebral fractures amounted to 6.2% in the 
placebo group versus 3.2% In alendronate group 
with a relative risk of 0.52. In the FIT study (10), 
4432 postmenopausal women with low BMD but 
without any preexisting vertebral fracture, were 
randomized to receive either alendronate or 
placebo. Alendronate treatment reduced the risk 
of vertebral fractures by 51%. Recently in 
another study, 1499 women who had been 
postmenopausal for at least 6 months, received 
alendronate 2.5, 5 mg/day or placebo for 2 years 
and 110 received estrogen plus progestin 
therapy (8). Estrogen plus progestin therapy 
provoked bone gains after 2 years and were 
slightly lighter than those in patients receiving 
alendronate 2.5 mg and 5 mg/day. Placebo 
group lost bone significantly both in spine and at 
hip. Both treatment regimens were well tolerated. 
Breakthrough bleeding was observed in 25% and 
30% of the patients in HRT and HRT alendronate 
combination groups respectively. Nevertheless 
only 5% of the patients discontinued treatment in 
each group due to bleeding. Mild stomach pain 
was experienced in only 2 patients in alendronate 
group.
Estrogen is effective in both prevention and 
treatment of postmenopausal osteoporosis, 
however bone loss resumes immediately after 
discontinuation of treatment (16). Conversely 
alendronate accumulates in bone and 
recirculates so accelerated bone loss is not 
observed when treatment is stopped (10,12).
Both HRT alone or HRT combined with 
alendronate treatments, showed significant 
increases in bone mineral densities of spine and 
femur neck. There is a trend towards a greater 
increase in bone mineral density especially at 
femur with alendronate and HRT combination 
treatment which did not achieve significance. 
Combination treatment appears to be a 
reasonable alternative in treatment. The weak 
point of this study is small sample size, 
nevertheless future studies with larger groups 
will enlighten the impact of adding alendronate 
to HRT In postmenopausal osteoporosis 
treatment.
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